Mostrar el registro sencillo del ítem
Incidence of Heart Failure following Exposure to a Protein Kinase Inhibitor (PKI), a French Population-based Study
| dc.rights.license | open | en_US |
| dc.contributor.author | ZELMAT, Yoann | |
| dc.contributor.author | CONTE, Cecile | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | NOIZE, Pernelle | |
| dc.contributor.author | VABRE, Clementine | |
| dc.contributor.author | PAJIEP, Marie | |
| dc.contributor.author | LAFAURIE, Margaux | |
| dc.contributor.author | LAPEYRE-MESTRE, Maryse | |
| dc.contributor.author | DESPAS, Fabien | |
| dc.date.accessioned | 2022-12-07T11:22:37Z | |
| dc.date.available | 2022-12-07T11:22:37Z | |
| dc.date.issued | 2023-04 | |
| dc.identifier.issn | 1365-2125 (Electronic) 0306-5251 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170496 | |
| dc.description.abstractEn | AIMS: Pharmacovigilance signals of heart failure (HF) following exposure to Protein Kinase Inhibitors (PKIs) have been detected in recent years. Our aim was to identify the PKIs most frequently associated with the development of HF. METHODS: Using the French National Healthcare Database, all patients newly exposed to a PKI between January 2011 and June 2014 were followed up for 18 months. Specific hospitalisation diagnosis and long-term HF-related disease codes were used to identify HF patients. HF Incidence Rate Ratios (IRR) were measured and adjusted Hazard Ratios (aHR) were estimated using a Cox model. Sensitivity analyses were performed to limit the potential indication and competitive risk bias. RESULTS: Thirteen PKIs were studied. Among the 49,714 new PKI users registered during the study period, the mean IRR of HF was 3.38 per 100 person-years, with a median time to onset of 155 days. We found a significant increase in the incidence of HF for 6 medicinal products: pazopanib (aHR= 2.42, 95% CI: 1.67-3.52), dasatinib (aHR= 2.22, 95% CI: 1.42-3.44), ruxolitinib (aHR= 2.11, 95% CI: 1.69-2.64), crizotinib (aHR= 1.71, 95% CI: 1.07-2.72), everolimus (aHR= 1.45, 95% CI: 1.26-1.67) and vemurafenib (aHR= 1.37, 95% CI: 1.01-1.86). Sensitivity analyses were consistent with our primary analysis. CONCLUSIONS: The current study provides knowledge on HF following exposure to a PKI. Additional studies could confirm these results for dasatinib, everolimus, pazopanib and ruxolitinib, and particularly for the two medicinal products with results slightly above the significance threshold, namely crizotinib and vemurafenib, in our sensitivity analyses. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Adverse drug reaction | |
| dc.subject.en | Heart failure | |
| dc.subject.en | Protein kinase inhibitor | |
| dc.title.en | Incidence of Heart Failure following Exposure to a Protein Kinase Inhibitor (PKI), a French Population-based Study | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/bcp.15576 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36285576 | en_US |
| bordeaux.journal | British Journal of Clinical Pharmacology | en_US |
| bordeaux.page | 1338-1348 | |
| bordeaux.volume | 89 | |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 4 | |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Ligue Contre le Cancer | en_US |
| bordeaux.identifier.funderID | Fondation ARC pour la Recherche sur le Cancer | en_US |
| hal.identifier | hal-03888322 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-12-07T11:22:46Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2023-04&rft.volume=89&rft.issue=4&rft.spage=1338-1348&rft.epage=1338-1348&rft.eissn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.issn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.au=ZELMAT,%20Yoann&CONTE,%20Cecile&NOIZE,%20Pernelle&VABRE,%20Clementine&PAJIEP,%20Marie&rft.genre=article |
